topotecan has been researched along with Disease Exacerbation in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.55) | 18.2507 |
| 2000's | 32 (48.48) | 29.6817 |
| 2010's | 30 (45.45) | 24.3611 |
| 2020's | 1 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Ackerman, JJH; Beeman, SC; Duan, C; Engelbach, JA; Garbow, JR; Ge, X; Perez-Torres, CJ; Rich, KM; Tsien, CI; Yang, R; Yuan, L | 1 |
| Bauer, F; Rao, V; Vredenburgh, JJ | 1 |
| Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J | 1 |
| Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kotake, M; Minato, K; Minemura, H; Nakamura, Y; Shibata, Y; Sugiyama, T; Yamada, Y | 1 |
| Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T | 1 |
| Agaoglu, FY; Cakir, FB; Darendeliler, E; Gorgun, O; Kebudi, R | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Beilken, A; Bochennek, K; Claviez, A; Dantonello, T; Dirksen, U; Klingebiel, T; Koscielniak, E; Sauerbrey, A | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM | 1 |
| Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH | 1 |
| Bruce, JN; DeLaPaz, R; Kennedy, BC; Surapaneni, K; Yanagihara, TK | 1 |
| Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J | 1 |
| Anderson, JR; Arndt, CA; Donaldson, SS; Hawkins, DS; Lyden, ER; Morris, CD; Rodeberg, DA; Wolden, SL | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Jamal, I; Jana, NR; Kumar, V; Sharma, A; Shekhar, S; Singh, BK; Vatsa, N | 1 |
| Barton, J; Burris, HA; Greco, FA; Infante, J; Jones, S; Patton, J; Shipley, D; Spigel, D; Thompson, D | 1 |
| Gomi, K; Hommura, F; Inage, M; Inoue, A; Inoue, C; Ishimoto, O; Maemondo, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T; Takanashi, S; Tsukamoto, T; Watanabe, H; Yamazaki, K; Yokouchi, H | 1 |
| Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V | 1 |
| Adjei, AA; Bryce, AH; Hillman, SL; Jett, JR; Kugler, JW; Mattar, B; Perez, EA; Rowland, K; Soori, G; Wender, DB | 1 |
| Berros, JP; Blay, P; Coto, PP; Estrada, E; Fernandez, Y; Fra, J; Gonzalez, EE; Izquierdo, M; Jimenez, P; Lacave, AJ; Luque, M; Muñiz, I; Muriel, C; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Kurzrock, R; Subbiah, V; Trent, JC | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M | 1 |
| Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L | 1 |
| Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Babilonti, L; Cormio, G; Ditto, A; Franchi, M; Ghezzi, F; Giorda, G; Giudici, S; Grijuela, B; Lorusso, D; Lorusso, M; Raspagliesi, F; Scambia, G; Zanaboni, F | 1 |
| Deppermann, M; Kaubitsch, S; Keppler, U; Korfel, A; Oehm, C; Thiel, E; von Pawel, J | 1 |
| Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P | 1 |
| Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S | 1 |
| Douillard, JY; Schiller, J | 1 |
| Cheung, NK; Kramer, K; Kushner, BH | 1 |
| Biasotti, S; De Bernardi, B; Garaventa, A; Haupt, R; Luksch, R; Mastrangelo, S; Pizzitola, MR; Podda, M; Prete, A; Severi, G; Viscardi, E | 1 |
| Lane, SR; Ross, GA; ten Bokkel Huinink, W | 1 |
| Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ | 1 |
| Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E | 1 |
| Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D | 1 |
| Herzog, TJ | 1 |
| Billups, CA; Davidoff, AM; Furman, WL; Hoffer, F; Houghton, PJ; Santana, VM; Stewart, CF | 1 |
| Barberi-Heyob, M; Chastagner, P; Marchal, C; Merlin, JL; Pinel, S; Taghian, A | 1 |
| Hunold, A; Jürgens, H; Liebscher, C; Paulussen, M; Ranft, A; Weddeling, N | 1 |
| Bernath, AM; Carroll, TJ; Foster, N; Hillman, S; Jett, JR; Lair, BS; Mailliard, JA; Molina, JR; Nikcevich, D; Tazelaar, HD | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Tada, A; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Forman, E; Greenlaw, C; Kalkunte, S; McCarten, K; Saulnier Sholler, GL | 1 |
| Grønlund, B | 1 |
| Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D | 1 |
| An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W | 1 |
| Alberts, DS; Benedetti, JK; Macdonald, JS; Modiano, M | 1 |
| Burger, PC; Friedman, HS; Heideman, RL; Horn, M; Kadota, RP; Kepner, JL; Kun, LE; Kuttesch, JF; Stewart, CF | 1 |
| Bate, WW; Grill, JP; Hatfield, AK; Jett, JR; Knost, JA; Marschke, RF; Schaefer, PL; Sloan, JA; Weitz, JJ; Zenk, DW | 1 |
| Cesano, A; Fields, SZ; Lane, SR; Ross, GA | 1 |
| Blessing, JA; Kilgore, LC; Mannel, R; Miller, DS; Van Le, L | 1 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D | 1 |
| Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP | 1 |
| Fisher, B; Johnson, DW; Macdonald, D; Roa, W; Won, M | 1 |
5 review(s) available for topotecan and Disease Exacerbation
| Article | Year |
|---|---|
Refractory Small Cell Carcinoma of the Ovary - Hypercalcemic Type (SCCOHT) Treated with Romidepsin and Topotecan: A Case Report and Review of the Literature.
Topics: Antibiotics, Antineoplastic; Carcinoma, Small Cell; Depsipeptides; Disease Progression; Fatal Outcome; Female; Humans; Ovarian Neoplasms; Ovariectomy; Topoisomerase I Inhibitors; Topotecan; Young Adult | 2016 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Databases, Factual; Disease Progression; Female; Humans; Injections, Intravenous; Karnofsky Performance Status; Life Tables; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Topotecan; Treatment Outcome | 2000 |
41 trial(s) available for topotecan and Disease Exacerbation
| Article | Year |
|---|---|
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2018 |
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden | 2018 |
Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome | 2013 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2015 |
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Molecular Targeted Therapy; Neoplasms; S Phase Cell Cycle Checkpoints; Sirolimus; Texas; Time Factors; Topotecan; Treatment Outcome; Young Adult | 2015 |
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease Progression; Disease-Free Survival; Female; Humans; Infant; Lymph Nodes; Male; Meningeal Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Topotecan; Treatment Failure; Tumor Burden; Vincristine | 2015 |
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Topotecan; Treatment Outcome | 2008 |
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Topics: Aged; Anthracyclines; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan | 2008 |
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
Topics: Administration, Oral; Adult; Aged; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Topotecan; Treatment Outcome | 2010 |
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prospective Studies; Survival; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2010 |
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan | 2011 |
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2013 |
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Disease Progression; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Prospective Studies; Survival Analysis; Topotecan | 2002 |
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease Progression; Doxorubicin; Female; Humans; Infant; Male; Neuroblastoma; Survival Analysis; Topotecan; Treatment Outcome; Vincristine | 2003 |
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan | 2004 |
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Topotecan | 2004 |
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome | 2004 |
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Disease Progression; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Male; Neuroblastoma; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Topotecan; Treatment Outcome | 2005 |
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carcinoma, Small Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome | 2006 |
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome | 2007 |
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan | 2006 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan | 1997 |
Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Female; Humans; Injections, Intravenous; Male; Middle Aged; Survival Analysis; Topotecan | 1997 |
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
Topics: Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Tomography, X-Ray Computed; Topotecan | 1999 |
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2000 |
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Cohort Studies; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leiomyosarcoma; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia; Topotecan; Uterine Neoplasms | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Disease Progression; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Ifosfamide; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Recurrence; Topotecan | 2002 |
Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome | 2002 |
20 other study(ies) available for topotecan and Disease Exacerbation
| Article | Year |
|---|---|
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms | 2023 |
Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
Topics: Animals; Benzylamines; Brain; Cyclams; Disease Models, Animal; Disease Progression; Female; Heterocyclic Compounds; Hypoxia-Inducible Factor 1, alpha Subunit; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Necrosis; Radiation Injuries, Experimental; Receptors, CXCR4; Topotecan | 2018 |
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Recurrence; Retreatment; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Dosimetry-based high-activity therapy with
Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult | 2019 |
A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Sarcoma, Ewing; Topotecan; Vincristine | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2015 |
Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.
Topics: Adult; Aged; Antineoplastic Agents; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Convection; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden | 2015 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; DNA Topoisomerases, Type I; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Neostriatum; Neurons; Topoisomerase I Inhibitors; Topotecan; Ubiquitin-Protein Ligases | 2017 |
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2009 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Long-term topotecan therapy in recurrent or persistent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Topotecan; Treatment Outcome | 2003 |
Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Mice; Mice, Nude; Topotecan; Transplantation, Heterologous | 2006 |
Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chagas Disease; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Neuroblastoma; Nifurtimox; Recurrence; Remission Induction; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |